Gary Titus insider trades: ImmunoCellular Therapeutics (IMUC) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Gary reports to the SEC
Open-market buys and sales
18 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Dec 20, 2013 | IMUC | ↑ Buy | 18,000 | $0.78 | $14K | Direct | Dec 20, 2013 (0d) |
| Jun 15, 2012 | SCLN | ↓ Sell | 81,607 | $7.00 | $571K | Direct | Jun 18, 2012 (3d) |
| May 31, 2012 | SCLN | ↑ Buy | 261 | $3.84 | $1K | Direct | Jun 18, 2012 (18d) |
| Feb 29, 2012 | SCLN | ↑ Buy | 711 | $3.85 | $3K | Direct | Apr 4, 2012 (35d) |
| Aug 18, 2011 | SCLN | ↑ Buy | 1,075 | $4.65 | $5K | Direct | Aug 18, 2011 (0d) |
| Jun 15, 2011 | SCLN | ↑ Buy | 2,455 | $4.81 | $12K | Direct | Jun 16, 2011 (1d) |
| Feb 28, 2011 | SCLN | ↑ Buy | 1,111 | $2.53 | $3K | Direct | May 16, 2011 (77d) |
| May 11, 2010 | SCLN | ↑ Buy | 2,500 | $3.39 | $8K | Direct | May 12, 2010 (1d) |
| May 22, 2009 | SCLN | ↑ Buy | 4,625 | $1.74 | $8K | Direct | May 26, 2009 (4d) |
| Dec 12, 2008 | SCLN | ↑ Buy | 15,000 | $1.01 | $15K | Direct | Dec 12, 2008 (0d) |
| Mar 31, 2008 | KOSN | ↑ Buy | 1,092 | $1.45 | $2K | Direct | Apr 2, 2008 (2d) |
| Mar 10, 2008 | KOSN | ↑ Buy | 3,040 | $1.31 | $4K | Direct | Mar 11, 2008 (1d) |
| Mar 5, 2008 | KOSN | ↑ Buy | 6,250 | $1.57 | $10K | Direct | Mar 6, 2008 (1d) |
| Oct 31, 2006 | KOSN | ↑ Buy | 10,000 | $3.99 | $40K | Direct | Nov 2, 2006 (2d) |
| Aug 30, 2006 | NUVO | ↓ Sell | 14,000 | $20.70 | $290K | Direct | Aug 31, 2006 (1d) |
| Aug 29, 2006 | NUVO | ↓ Sell | 6,831 | $20.65 | $141K | Direct | Aug 30, 2006 (1d) |
| Aug 25, 2006 | NUVO | ↓ Sell | 30,000 | $19.92 | $598K | Direct | Aug 28, 2006 (3d) |
| Aug 24, 2006 | NUVO | ↓ Sell | 15,000 | $19.50 | $293K | Direct | Aug 25, 2006 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Gary Titus's insider trades
Gary Titus is Chairman and Secretary at ImmunoCellular Therapeutics (IMUC). Since Aug 24, 2006, Gary has reported 13 open-market purchases worth $124K and 5 sales worth $1.9M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (16 filings), option exercises (6 filings), other transactions (3 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every IMUC insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.